LH

Laboratory Corporation of America Holdings

189.5600
USD
0.40%
189.5600
USD
0.40%
140.5300 196.3600
52 weeks
52 weeks

Mkt Cap 18.71B

Shares Out 98.68M

Chat
Send me real-time posts from this site at my email

Laboratory Corporation of America Holdings

SUMMARY

The following summary is qualified in its entirety by the more detailed information included elsewhere in this prospectus supplement and the accompanying prospectus. Because this is a summary, it may not contain all the information that may be important to you. You should read the entire prospectus supplement and the accompanying prospectus, including the “Risk Factors” section in this prospectus supplement, and the financial statements and the notes to those statements and other information incorporated by reference, before making a decision whether to invest in the Notes.

The Company

Laboratory Corporation of America® Holdings is a leading global life sciences company that is deeply integrated in guiding patient care. The Company provides comprehensive clinical laboratory and end-to-end drug development services through LabCorp Diagnostics (LCD) and Covance Drug Development (CDD). LabCorp is positioned at the convergence of research and care delivery to enable more precise and individualized healthcare, bringing together world-class diagnostics and drug development capabilities. With nearly 61,000 employees worldwide, the Company’s mission is to improve health and improve lives by delivering world-class diagnostics, accelerating the availability of innovative medicines to patients, and using technology to change the way care is delivered.

The Company provides diagnostic, drug development and technology-enabled solutions for more than 120 million patient encounters per year. The Company typically processes tests on more than 2.5 million patient specimens per week and also supports clinical trial activity in approximately 100 countries through its industry-leading central laboratory, preclinical, and clinical development businesses, generating more safety and efficacy data to support drug approvals than any other company.

The Company, a Delaware corporation, is headquartered in Burlington, North Carolina, and was incorporated in 1971. The Company has continually expanded and diversified its business offerings, technological expertise, geographic reach, revenue base, and financial growth opportunities through a combination of organic investments and disciplined acquisitions.

Our principal executive offices are located at 358 South Main Street, Burlington, North Carolina 27215, and our telephone number at that address is (336) 229-1127.

Concurrent Cash Tender Offer

On November 18, 2019, we announced a cash tender offer (the “Tender Offer”) to purchase up to $300,000,000 principal amount of our outstanding $600,000,000 aggregate principal amount of 4.625% Senior Notes due 2020 (the “2020 Notes”). We are permitted, among other things, to amend, extend, terminate or withdraw the Tender Offer, including by increasing or decreasing the principal amount of 2020 Notes we may purchase in the Tender Offer, and there can be no assurance as to the principal amount of 2020 Notes that will be tendered or accepted for purchase pursuant to the Tender Offer. The Tender Offer is subject to certain conditions, including the consummation of this offering. This offering is not contingent upon the completion of the Tender Offer.

We may use a portion of the net proceeds from the sale of the Notes offered by this prospectus supplement to purchase the 2020 Notes that are tendered by holders and accepted by us in the Tender Offer. See “Use of Proceeds” in this prospectus supplement.

This prospectus supplement is not an offer to purchase or a solicitation of an offer to sell the 2020 Notes. The Tender Offer is being made only by and pursuant to the terms of a separate offer to purchase.

S-3


More
Followers
3

Welcome!!! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue